EN - News

Ontario Is Looking At Using An Antidepressant As A Treatment For Mild COVID-19

Fluvoxamine will possibly be considered for mild patients within a week of symptoms.

Antidepressants are commonly used to treat depression, but they may serve another purpose in Ontario for mild COVID-19 patients.

Fluvoxamine was listed as a possible treatment for mild COVID-19 in adult patients in a panel from Ontario's Science Advisory Table on December 20.

The panel, which features "Therapeutic Management of Adult Patients with COVID-19," suggests that individuals over 18 years old may be able to use Fluvoxamine in a 15-day stint within a week of symptoms appearing for "mildly ill patients."

Ontario's Science Advisory Table says the recommendation for this treatment was pushed forward due to "very low certainty evidence of reduction in hospitalization" and "the need for outpatient treatment options with a reasonable safety profile" when it comes to the province's rising cases and the Omicron variant.

If the drug is used, Ontario's Science Advisory Table says, "Pharmacist consultation and outpatient provider follow-up is important to avoid any significant adverse drug interactions with fluvoxamine."

The advisory table also lists a variety of other treatment options on the sheet as well to be considered. The recommendations differ between mildly, moderately and critically ill patients.

The panel also clarifies that the recommendations listed "are based on the best available data and may change as additional data becomes available."

Ontario has seen an uptick in COVID-19 cases due to the Omicron variant and has responded with stronger restrictions, including 50% capacity limits for certain establishments, social gathering limits indoors and outdoors and a host of new rules for restaurants in an attempt to curb the spread.